CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 10:30 a.m. PT (1:30 p.m. ET) in San Francisco, CA.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com.  An archived replay will be available for approximately 30 days following the presentation.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com

Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.